Advanced search
Publication Cover
Leukemia & Lymphoma Volume 9, 1993 - Issue 6
Submit an article Journal homepage
23
Views
4
CrossRef citations to date
0
Altmetric
Original Article

C-Reactive Protein (CRP) Levels Do Not Reflect Disease Status in Patients with Multiple Myeloma

R. D. Brown Haematology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
,
L. Snowdon Haematology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
,
E. Uhr Haematology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
,
J. Gibson Haematology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
&
D. Joshua Haematology Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Pages 509-512 | Received 20 Aug 1992, Published online: 01 Jul 2009

References

  • Bataille R., Dune B., Geiner J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. British Journal of Haematology 1983; 55: 439–447
  • Simonsson B., Kallander C. F. R., Brenning G., Killander A., Gronowitz J. S., Bergstrom R., Ahre A. Biochemical markers in multiple myeloma. British Journal of Haematology 1985; 69: 47–53
  • Cruzick J., Cooper E. H., MacLennan I. C. M. The prognostic value of serum B2 microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer 1985; 52: 14
  • Griepp P. R., Kyle R. A. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood 1983; 62: 166–171
  • Brown R. D., Ioannidis R. A., Joshua D. E., Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Australian and New Zealand Journal of Medicine 1989; 19: 226–232
  • Cimino G., Avvisati G., Amadori S., Cava M. C., Gianarelli D., Di Nucci G. D., Magliocca V., Petrucci M. T., Poti G., Sgadari C., Mandelli F. High serum Interleukin-2 levels are predictive of prolonged survival in multiple myeloma. British Journal of Haematology 1990; 75: 373–377
  • Bataille R., Klein B. Serum B-2-microglobulin (B2M) in myeloma : towards a simple prognostic stratification using B2m and acute phase proteins?. Blood 1991; 77: 1616
  • Dune B. Response. Blood 1991; 77: 1616–1617
  • Pilen A., Boccadoro M., Battaglio S., Diazani U., Massaia M., Omede P., Palumbo A. P., Klein B., Bataille R. New prognostic factors in multiple myeloma. Multiple Myeloma from Biology to Therapy, A. Pileri, M. Boccadoro. Torino, Cassa di Risparmio 1991; 81–82
  • Heinrich P. G., Castell J. V., Andus T. Interleukin 6 and the acute phase response. Biochemical Journal 1990; 265: 621–626
  • Ishimi Y., Miyauna C., Jin C. H., Akatsu T., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T. IL-6 is produced by osteoblasts and induces bone resorption. Journal of Immunology 1990; 145: 3297–3303
  • Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term marrow cultures by inducing IL-1 release. Journal of Immunology, 144: 4226–4230
  • Bataille R., Jourdan M., Zhang X. -G., Klein B. Serum levels of lnterleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Blood 1989; 84: 2008–2011
  • Brown R. D., Joshua D. E., Uhr E., Snowdon L., Gibson J. The use of a commercially available immunoassay to determine the level of Interleukin-6 in the serum of patients with multiple myeloma. Leukaemia and Lymphoma 1991; 5: 151–155
  • Nachbauer D. M., Herold M., Maneschg A., Huber H. Serum levels of interleukin-6 in multiple myeloma and other haematological disorders: correlation with disease activity and other prognostic parameters. Annals of Hematology 1991; 62: 54–58

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.